



<b>Name</b>	Jwa Hoon Kim
<b>Affiliation</b>	Division of Medical Oncology, Department of Internal Medicine, Korea University College of Medicine, Korea University Anam Hospital
<b>Country</b>	Republic of Korea
<b>Major Field</b>	Gastrointestinal tract cancer

### Educational Background

2005. 3 – 2011. 2 M.D., University of Kyung-hee, College of Medicine, Seoul, South Korea  
 2014. 3 – 2016. 2 Master, University of Ulsan, College of Medicine, Seoul, South Korea  
 2020. 3 – 2022. 2 Ph.D., University of Ulsan, College of Medicine, Seoul, South Korea

### Professional Experience

2011-2016 Internship & Resident physician, Department of Internal Medicine, Asan Medical Center  
 2019-2021 Fellowship, Department of Oncology, Asan Medical Center  
 2021- Assistant professor, Division of Medical Oncology, Department of Internal Medicine, Korea University Anam Hospital

### Main Scientific Publications

1. Kim JH, Ryu MH, Park YS, Ma J, Lee SY, Kim D, Kang YK. Predictive biomarkers for the efficacy of nivolumab as  $\geq$  3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial. *BMC Cancer*. 2022 Apr 9;22(1):378.
2. Kim JH, Yoo C, Seo S, Jeong JH, Ryoo BY, Kim KP, Lee JB, Lee KW, Kim JW, Kim IH, Kang M, Ryu H, Cheon J, Park SR. A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY. *Cancers (Basel)*. 2022 Jan 22;14(3):559.
3. Kim JH, Ahn B, Hong SM, Jung HY, Kim DH, Choi KD, Ahn JY, Lee JH, Na HK, Kim JH, Kim YH, Kim HR, Lee HJ, Kim SB, Park SR. Real-World Efficacy Data and Predictive Clinical Parameters for Treatment Outcomes in Advanced Esophageal Squamous Cell Carcinoma Treated with Immune Checkpoint Inhibitors. *Cancer Res Treat*. 2022 Apr;54(2):505-516.
4. Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. *Liver Cancer*. 2021 Apr;10(2):107-114.
5. Kim HD, Kim JH, Ryu YM, Kim D, Lee S, Shin J, Hong SM, Kim KH, Jung DH, Song GW, Hwang DW, Lee JH, Song KB, Ryoo BY, Jeong JH, Kim KP, Kim SY, Yoo C. Spatial Distribution and Prognostic Implications of Tumor-Infiltrating FoxP3- CD4+ T Cells in Biliary Tract Cancer. *Cancer Res Treat*. 2021 Jan;53(1):162-171.
6. Kim JH, Kim SY, Baek JY, Cha YJ, Ahn JB, Kim HS, Lee KW, Kim JW, Kim TY, Chang WJ, Park JO, Kim J, Kim JE, Hong YS, Kim YH, Kim TW. A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer. *Cancer Res Treat*. 2020 Oct;52(4):1135-1144.



7. Kim JH, Kim SY, Kim KP, Kim TW, Chae SY, Kim HJ, Kim JS, Ryu JS, Moon DH, Kim JE, Hong YS. Regorafenib-Induced Hypothyroidism as a Predictive Marker for Improved Survival in Metastatic or Unresectable Colorectal Cancer Refractory to Standard Therapies: A Prospective Single-Center Study. *Target Oncol.* 2019 Dec;14(6):689-697.
8. Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, Kim BS, Yoo MW, Yook JH, Kim BS, Kim KH, Kim CW, Kang YK. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience. *Cancer Med.* 2019 Mar;8(3):1034-1043.
9. Kim JH, Jeong JH, Ryoo BY, Kim KP, Chang HM, Oh D, Song TJ, Lee SS, Seo DW, Lee SK, Kim MH, Park Y, Kwon JW, Hwang DW, Lee JH, Lee W, Kim SC, Yoo C, Song KB. Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. *Cancer Res Treat.* 2021 Apr;53(2):424-435.
10. Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J, Byeon SJ, Kang YK. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. *Cancer Res Treat.* 2018 Apr;50(2):518-529.